Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: A systematic review
Top Cited Papers
- 17 December 2012
- journal article
- review article
- Published by Elsevier BV in Vaccine
- Vol. 31 (1), 96-108
- https://doi.org/10.1016/j.vaccine.2012.10.103
Abstract
No abstract availableKeywords
Funding Information
- Bill & Melinda Gates Foundation
This publication has 96 references indexed in Scilit:
- Economic evaluation of pneumococcal conjugate vaccination in The GambiaBMC Infectious Diseases, 2010
- The Cost‐Effectiveness of Rotavirus Vaccination in MalawiThe Journal of Infectious Diseases, 2010
- Rotavirus Disease Burden and Impact and Cost‐Effectiveness of a Rotavirus Vaccination Program in KenyaThe Journal of Infectious Diseases, 2009
- The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South AfricaVaccine, 2009
- Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in ChinaHepatology, 2009
- Cost-Effectiveness Analysis of a Quadrivalent Human Papilloma Virus Vaccine in MexicoArchives of Medical Research, 2009
- Cost-effectiveness of introducing a rotavirus vaccine in developing countries: The case of MexicoBMC Infectious Diseases, 2008
- Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countriesVaccine, 2008
- Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in IndiaBritish Journal of Cancer, 2008
- Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implicationsReproductive Health Matters, 2008